Clinical trial
Rosiglitazone Versus a Sulfonylurea On Progression Of Atherosclerosis In…
NCT00116831 · GlaxoSmithKline, Industry · Completed
Key facts
| NCT number | NCT00116831 |
|---|---|
| Title | Rosiglitazone Versus a Sulfonylurea On Progression Of Atherosclerosis In Patients With Heart Disease And Type 2 Diabetes |
| Official title | A Phase III, 18 Month, Multicenter, Randomized, Double-Blind, Active-Controlled Clinical Trial to Compare Rosiglitazone Versus Glipizide on the Progression of Atherosclerosis in Subjects With Type 2 Diabetes Mellitus and Cardiovascular Disease (APPROACH) |
| Lead sponsor | GlaxoSmithKline, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Atherosclerosis |
| Intervention type | Drug |
| Interventions | Glipizide, rosiglitazone maleate |
| Enrollment | 672 |
| Start date | Jan 1, 2005 |
| Primary completion | Aug 1, 2008 |
| Completion | Aug 1, 2008 |
| First posted | Jul 1, 2005 |
| Last update posted | Mar 23, 2017 |
| Countries | Argentina, Brazil, Canada, Czechia, France, Germany, Greece, Hong Kong, India, Italy, Latvia, Mexico and 8 more |
At a glance
- 100–999 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: